Cost Comparison
Adverse Event Cost Comparison– Data Collection & Analysis
- Comparison of Treatment Costs of Grade 3/4 Adverse Events associated
with erlotinib or pemetrexed maintenance therapy for Patients
with advanced non-small-cell lung cancer (NSCLC) in Germany, France,
Italy, and Spain
Banz K, Bischoff H, Brunner M, Chouaid C,de Castro Carpeño J,de Marinis F, Grossi F, Vergnenègre A, Walzer S; LungCancer 2011 (in press)
Adverse Event Cost Comparison- Analysis
- Costs of managing adverse events in the treatment of first-line
metastatic renal cell carcinoma: bevacizumab in combination with
interferon-a2a compared with sunitinib
Mickisch G, Gore M, Escudier B, Procopio G, Walzer Sand Nuijten MJ; BritishJournal of Cancer (2009), 1-7
Cost Comparison
- Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany
Bischoff HG, Heigener DF, Walzer S, Nuijten MJ; LungCancer 2010: 69S1 (2010): S18-S23
Cost Comparison
- A cross-market cost comparison of erlotinib versus pemetrexed
for first-line maintenance treatment of patients with locally advanced
or metastatic non-small-cell lung cancer
Nuijten MJC, de Castro Carpeño J, ChouaidC, Vergnenègre A, Grossi F, Bischoff H, Heigener D, Walzer S; XXX2011: submitted
Online
PDF